Trial Profile
Sequential Expansion of Comparative Effectiveness of Oral Anticoagulants: A Cohort Study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Jun 2022
Price :
$35
*
At a glance
- Drugs Dabigatran etexilate (Primary) ; Warfarin
- Indications Embolism and thrombosis; Haemorrhage; Stroke
- Focus Adverse reactions; Therapeutic Use
- Acronyms RE-LY
- Sponsors Boehringer Ingelheim
- 18 May 2022 Results an analysis assessing cost-effectiveness of dabigatran compared to acenocoumarol, rivaroxaban and apixaban for thromboembolic events prevention in atrial fibrillation patients using clinical data from this trial and from a NMA published by Lopez-Lopez et al presented at the 27th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research
- 25 Aug 2021 Results assessing Plasmode Simulation of Covariate Misclassification and Transportability from individual-level data from the Randomized Evaluation of Long-Term Anticoagulation (RE-and target population of warfarin initiators in a 20% random sample of Medicare participants LY) trial presented at the 37th International Conference on Pharmacoepidemiology and Therapeutic Risk Management
- 20 Mar 2021 Results (n=18113) assessing patients at risk for cardiovascular events according to their pharmacological treatment intensity and adherence, published in the American Journal of Cardiology.